Articles

Monitoring multiple myeloma by quantification of recurrent mutations in serum

Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;Norwegian Cancer Genomics Consortium, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;CEMIR – Center for Molecular Inflammation Research, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Norwegian Cancer Genomics Consortium, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;Institute for Clinical Science, University of Bergen, Trondheim, Norway;Institute for Cancer Research, Oslo University Hospital, Trondheim, Norway
Norwegian Cancer Genomics Consortium, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;Institute for Cancer Research, Oslo University Hospital, Trondheim, Norway
Department of Pathology and Medical Genetics, St. Olav’s University Hospital, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;CEMIR – Center for Molecular Inflammation Research, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;Norwegian Cancer Genomics Consortium, Norwegian University of Science and Technology, NTNU, Trondheim, Norway;Department of Hematology, St. Olav’s University Hospital, Trondheim, Norway
Vol. 102 No. 7 (2017): July, 2017 https://doi.org/10.3324/haematol.2016.160564